Meeting
2013 ASCO Annual Meeting
A large retrospective analysis of trabectedin in 885 patients with advanced soft tissue sarcoma.
Authors
Axel Le Cesne
Institut Gustave Roussy, Villejuif, France
Axel Le Cesne , Isabelle Ray-Coquard , Florence Duffaud , Christine Chevreau , Nicolas Penel , Binh Bui , Sophie Piperno-Neumann , Corinne Delcambre , Maria Rios , Loic Chaigneau , Christine Le Maignan , Cecile Guillemet , François Bertucci , Emmanuelle Bompas , Claude Linassier , Olivier Collard , Caroline Even , Francoise Ducimetiere , Philippe Cousin , Jean-Yves Blay
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 31, 2013 (suppl; abstr 10563)
DOI
10.1200/jco.2013.31.15_suppl.10563
Abstract #
10563
Poster Bd #
46E
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Trabectedin for advanced soft tissue sarcoma: Ten-year real-life perspective.
First Author: Sivan Shamai
Poster
2022 ASCO Annual Meeting
Trabectedin in advanced retroperitoneal well differentiated/dedifferentiated liposarcoma and leiomyosarcoma (TRAVELL): Results of a phase 2 study from Italian sarcoma group (ISG).
First Author: Roberta Sanfilippo
Poster
2022 ASCO Annual Meeting
Five-year results of a phase 2 trial using ipilimumab (I), nivolumab (N), and trabectedin (T) for previously untreated advanced soft tissue sarcoma (NCT03138161).
First Author: Erlinda Maria Gordon
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo